Navigation Links
Phase II study of an oral therapy for Gaucher disease yields positive results
Date:5/3/2010

(WASHINGTON, May 3, 2010) Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.

Gaucher disease is a genetic disorder affecting an estimated 1 in 50,000 to 1 in 100,000 people in the U.S. population. Gaucher disease occurs when a mutation of the glucocerebrosidase gene causes low activity of that enzyme in the body. As a result, harmful fatty substances accumulate in the liver, spleen, bones, and bone marrow, preventing cells and organs from working properly. The primary treatment option is enzyme replacement therapy, which is given intravenously, to break down the accumulated fatty substances.

Eliglustat tartrate is an oral drug currently in development for Gaucher disease type 1 (GD1). As a substrate reduction therapy, the drug decreases the body's production of the fatty substances so they do not accumulate in cells. Based on Phase I trials in healthy volunteers that demonstrated positive initial safety results, the research team initiated a multinational, open-label, single-arm Phase II study of 26 GD1 patients to evaluate the efficacy, safety, and pharmacokinetics (how the body absorbs and processes the drug) of eliglustat tartrate administered orally at 50mg or 100mg doses twice daily. Eligible patients had confirmed Gaucher disease, characterized as enzyme deficiency and a spleen volume at least 10 times greater than normal, plus abnormal values of either platelet count or hemoglobin levels.

"As with many other rare conditions, we strive to develop new options with improved efficacy and safety for our patients, but we also look for options that may be easier on the provider and the patient.In this case, we were hoping an oral alternative would be viable," said lead study author Elena Lukina, MD, of the Hematology Research Center at the Russian Academy of Medical Sciences in Moscow, Russia.

The study endpoint (improvement in at least two of the three main efficacy parameters: spleen volume, hemoglobin level, and platelet count) was met by three-fourths (77%) of all patients and nearly all (91%) of the 22 patients who completed the full 52 weeks, with the greatest overall improvements seen in hemoglobin level and spleen volume. The research team found statistically significant improvements across many disease symptoms, including mean hemoglobin level, platelet count, spleen volume, liver volume, and lumbar spine bone mineral density. Furthermore, the patients' glucosylceramide plasma levels normalized. Disease symptoms seemed to respond rapidly, and improvement was seen especially in bone mineral density. This may have resulted from the drug's small molecular size, which allows it to diffuse quickly within affected cells.

"Eliglustat tartrate provides promise for a safe, effective, and convenient oral therapy for patients with Gaucher disease type 1," said Dr. Lukina.

Further clinical development of eliglustat tartrate is already proceeding with larger, controlled Phase III studies in untreated patients and in patients previously stabilized with imiglucerase an intravenously administered medication currently used to treat Gaucher disease.


'/>"/>

Contact: Wendy Stokes
webmaster@hematology.org
202-776-0544
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
2. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
3. Southampton scientists begin Phase II patient trial for new asthma treatment
4. Intellicate Announces New “Phased Return to Work” (PRtW) Service
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
7. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
8. New High Purity Immunoglobulin Enters Phase III in Europe and the US
9. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
10. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
11. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... ... From May 4 to 6, EarQ and Signia co-sponsored a ... more about Signia’s technology and the successful business and marketing techniques that make EarQ ... practices succeed in this highly competitive industry,” said Ed Keller, president of EarQ. “This ...
(Date:5/6/2016)... Diego, CA (PRWEB) , ... May 06, 2016 , ... ... Companies, has been family-owned and operated for over 35 years. Maintaining core values of ... has driven their success and made them a leading name in San Diego plumbing, ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... System and David Konur, CEO of Cardiovascular Institute of the South announced today ... be performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pivot Point Consulting ... gold standard KLAS Performance Report, Epic Consulting 2016 - Which Firms ... specialize in consulting services for electronic health record (EHR) solutions from Epic ...
(Date:5/5/2016)... Tampa, FL (PRWEB) , ... May 05, 2016 ... ... hospital in Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative ... (LAAC) Implant. Since first offering the procedure in April of 2015, Florida Hospital ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
(Date:5/3/2016)... Global Insulin Needles Industry ... key companies and supported with 272 tables and ... on the current state of the Insulin Needles ... including definitions, classifications, applications and industry chain structure. ... the international market including development history, competitive landscape ...
(Date:5/3/2016)... May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, ... - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
Breaking Medicine Technology: